Soleno Therapeutics (SLNO)

Executive Summary

Soleno Therapeutics is a commercial-stage biopharmaceutical company focused on rare genetic disorders, with its lead product VYKAT XR approved by the FDA for hyperphagia in Prader-Willi syndrome (PWS). The company has transitioned successfully from development to commercialization, leveraging a patient-centric approach to address unmet needs in orphan diseases. Its pipeline includes DCCR (diazoxide choline), an investigational therapy for PWS currently in Phase 3 trials (NCT05701774), and a Phase 2 program for SH2B1 deficiency obesity. The ongoing Phase 3 trial for DCCR in PWS is active, with a completion date in 2028, while the Phase 2 study for SH2B1 deficiency obesity has unknown status. Soleno's commercial execution with VYKAT XR provides a revenue base, and the pipeline offers upside potential. Key upcoming catalysts include data readouts from the DCCR Phase 3 program and potential expansion into new indications, which could significantly impact valuation.

Upcoming Catalysts (preview)

• Q2 2027DCCR Phase 3 PWS Trial Data Readout60% success
• TBDPhase 2 SH2B1 Deficiency Obesity Results30% success
• Q4 2026VYKAT XR Commercial Revenue Update90% success